Stroke Prevention in Atrial Fibrillation

Stroke Prevention in Atrial Fibrillation
  • Author : Greg Flaker
  • Publisher : Elsevier Health Sciences
  • Release : 24 May 2018
GET THIS BOOKStroke Prevention in Atrial Fibrillation

Get a quick, expert overview of stroke risks among patients with treated and untreated atrial fibrillation, in addition to best practices for management and treatment of patients with atrial fibrillation to minimize stroke risks. This concise, clinically-focused resource by Dr. Greg Flaker consolidates today’s available information on this timely topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee cardiologists as well as general practitioners treating and monitoring these patients. Covers a broad spectrum

Stroke Prevention in Atrial Fibrillation

Stroke Prevention in Atrial Fibrillation
  • Author : Renato D. Lopes,Duke University Evidence-based Practice Center
  • Publisher : Unknown Publisher
  • Release : 24 January 2022
GET THIS BOOKStroke Prevention in Atrial Fibrillation

OBJECTIVES: Oral anticoagulation with vitamin K antagonists (VKAs) has long been the gold standard therapy for stroke prevention in nonvalvular atrial fibrillation (AF). Limitations in monitoring and compliance of VKAs have fueled the development of new antithrombotic strategies, devices, and oral anticoagulants, including oral direct thrombin inhibitors and factor Xa inhibitors. This review updates previous reviews, particularly with regard to these newer treatment options and the optimal risk stratification tools for stroke and bleeding prediction. DATA SOURCES: We searched PubMed(

Quick Pocket Guide to New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Quick Pocket Guide to New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
  • Author : Luca Masotti,Mario Di Napoli,Daniel A. Godoy,Roberto Cappelli
  • Publisher : SEEd
  • Release : 05 June 2012
GET THIS BOOKQuick Pocket Guide to New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Cardioembolic strokes account for one third of ischemic strokes and atrial fibrillation (AF) representing the main source of this stroke subtype. The rate of stroke is 5%/year in patients with AF. Patients with AF have a 2-7 fold increased risk of stroke compared to patients without. Stroke prevention in atrial fibrillation (SPAF) is therefore of utmost importance and represents a major point in the modern management of AF. This booklet provides an overview of new oral anticoagulants used, listing their

Stroke Prevention in Patients with Atrial Fibrillation

Stroke Prevention in Patients with Atrial Fibrillation
  • Author : Gillian D. Sanders,Duke University Evidence-based Practice Center
  • Publisher : Unknown Publisher
  • Release : 24 January 2022
GET THIS BOOKStroke Prevention in Patients with Atrial Fibrillation

OBJECTIVE: This review updates previous reviews regarding the optimal risk stratification tools for stroke and bleeding prediction, and treatment options for stroke prevention in patients with atrial fibrillation. DATA SOURCES: We searched PubMed(r), Embase(r), and the Cochrane Database of Systematic Reviews for relevant English-language comparative studies published from January 1, 2000, to February 14, 2018. REVIEW METHODS: Two investigators screened each abstract and full-text article for inclusion, abstracted data, rated quality and applicability, and graded evidence. When possible, random-effects models were used

Left Atrial Appendage Closure

Left Atrial Appendage Closure
  • Author : Jacqueline Saw,Saibal Kar,Matthew J. Price
  • Publisher : Springer
  • Release : 09 November 2015
GET THIS BOOKLeft Atrial Appendage Closure

Percutaneous left atrial appendage (LAA) closure is an emerging technology for thromboembolic prevention in patients with atrial fibrillation (AF). The first human implantation of an LAA device occurred in 2001, and since then four devices have received CE mark approval. These devices are being widely used in Europe for LAA closure in patients who are poor candidates for long-term oral anticoagulation. In the US, the WATCHMAN device (Boston Scientific) is anticipated to receive FDA approval imminently for AF patients who are

Stroke Prevention in Atrial Fibrillation

Stroke Prevention in Atrial Fibrillation
  • Author : U. S. Department Of Heal Human Services,Agency for Healthcare Resea And Quality
  • Publisher : CreateSpace
  • Release : 01 September 2013
GET THIS BOOKStroke Prevention in Atrial Fibrillation

Atrial fibrillation (AF) is a common type of supraventricular tachyarrhythmia. While a supraventricular tachyarrhythmia is a tachycardic rhythm originating above the ventricular tissue, AF is characterized by uncoordinated atrial activation with consequent deterioration of mechanical function. AF is the most common cardiac arrhythmia in clinical practice, accounting for approximately one-third of hospitalizations for cardiac rhythm disturbances. The estimated prevalence of AF is 0.4% to1 % in the general adult population, occurring in about 2.2 million people in the U.S. The prevalence increases

Stroke Prevention in Clinical Practice

Stroke Prevention in Clinical Practice
  • Author : Daryll M. Baker
  • Publisher : Springer Science & Business Media
  • Release : 10 December 2007
GET THIS BOOKStroke Prevention in Clinical Practice

Primary care physicians are the first to diagnose transient ischaemic attacks (TIAs), and are the doctors who can undertake a considerable amount of stroke prevention treatment. This book fills the primary care physician’s need for a short clear text explaining how to accurately diagnose a TIA, determine what investigations are indicated and how and when to intervene to reduce the risk of stroke. Short chapters are written in point form with clear diagrams and figures, each chapter written by

Dabigatran for Stroke Prevention in Atrial Fibrillation

Dabigatran for Stroke Prevention in Atrial Fibrillation
  • Author : Anonim
  • Publisher : Unknown Publisher
  • Release : 24 January 2022
GET THIS BOOKDabigatran for Stroke Prevention in Atrial Fibrillation

Atrial fibrillation (AF) is a type of cardiac dysrhythmia that is estimated to affect between 200,000 and 250,000 Canadians. 1 Stroke is an important cause of disability and death from AF, where approximately 15% of strokes are caused by AF. A new class of oral anticoagulants, the direct thrombin inhibitors, has been developed. Dabigatran etexilate (Pradax) is the first of a new class of oral anticoagulants to reach the market. 5 With a more targeted mechanism of anticoagulation, dabigatran offers several potential clinical advantages over

Stroke Prevention in Atrial Fibrillation 2012

Stroke Prevention in Atrial Fibrillation 2012
  • Author : American College of Chest Physicians,International Guidelines Center (Igc)
  • Publisher : Unknown Publisher
  • Release : 20 February 2012
GET THIS BOOKStroke Prevention in Atrial Fibrillation 2012

GUIDELINES Pocketcards(tm) are multifold pocketcards containing society-endorsed, evidence-based treatment guidelines in a brief algorithmic format that is most preferred by practicing clinicians, quality managers, nurses, educators, and medical students. The Stroke Prevention in Atrial Fibrillation GUIDELINES Pocketcard(tm) is endorsed by the American College of Chest Physicians (ACCP) and based on the 9th Edition of Antithrombotic Therapy and Prevention of Thrombosis Evidence-Based Clinical Practice Guidelines. This practical quick-reference tool contains a CHADS2 risk assessment, detailed treatment recommendations and summary